Incidence, outcomes, and risk factors of antituberculosis drugs induced liver injury in Thailand: A retrospective cohort study

被引:0
|
作者
Akkahadsee, Pattaraporn [1 ]
Jantharaksa, Sirot [1 ]
Sawangjit, Ratree [2 ]
Phumart, Panumart [3 ]
机构
[1] Mahasarakham Hosp, Maha Sarakham, Thailand
[2] Mahasarakham Univ, Fac Pharm, Dept Clin Pharm, Clin Trials & Evidence Based Synth Res Unit CTEBs, Maha Sarakham, Thailand
[3] Khon Kaen Univ, Dept Social & Adm Pharm, Khon Kaen, Thailand
来源
PHARMACY PRACTICE-GRANADA | 2024年 / 22卷 / 02期
关键词
tuberculosis; drug-induced liver injury; hepatotoxicity; risk factors; INDUCED HEPATOTOXICITY; TUBERCULOSIS PATIENTS; POLYMORPHISMS; PREVALENCE; MANAGEMENT; REGIMENS; HIV;
D O I
10.18549/PharmPract.2024.2.2965
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Tuberculosis (TB) is a persistent health concern in numerous regions, including Thailand. The adverse effects of tuberculosis (TB) treatments, particularly liver injuries, can complicate treatment protocols, thereby increasing the likelihood of treatment discontinuation and the risk of subsequent drug resistance. Objective: This study was conducted to investigate the incidence, predisposing factors, and treatment outcomes associated with antituberculosis drugs induced liver injury (ATDILI) in Northeastern Thailand. Methods: A retrospective analysis was conducted at Mahasarakham Hospital in 2019. Patient data were retrieved from hospital records and databases. Inclusion criteria included receiving a first-time TB diagnosis, starting a standard TB regimen, and having normal liver function. To compare baseline characteristics between ATDILI patients and controls, Chi-square tests and T -tests were used. Bivariate and multivariable regression analyses were conducted to identify factors associated with drug -induced hepatitis. Results: 346 of 602 TB patients (57.5%) were enrolled. The study found an incidence of ATDILI at 14.45% (50 cases), which is notably higher than the Thai average of 4.8%. Risk factors were identified as malnutrition (adjusted OR=6.71, 95%CI 3.11:14.45), concurrent diseases (adjusted OR=2.42, 95%CI 1.20:4.89), and alcohol consumption (adjusted OR=4.24, 95%CI 1.45:12.38). In terms of therapeutic outcomes, only 18 patients were cured (36.0%). The probability of hepatotoxic events was addressed during the initial treatment phase, emphasizing the critical need for rigorous liver function monitoring during the first month of TB therapy. The ATDILI group had a mortality rate of 16%, which was higher than the national TB -related average of 8.2%. Conclusion: The marked presence of ATDILI in the cohort under study accentuates the immediate need for enhanced clinical monitoring, especially among susceptible groups. It is imperative to implement strategies aimed at early detection, prompt intervention, and holistic management of ATDILI, complemented by endeavors to boost cure rates for the affected population.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Incidence, risk factors and maternal outcomes of unsuspected placenta accreta spectrum disorders: a retrospective cohort study
    Zhao, Jianlin
    Li, Qin
    Liao, E.
    Shi, Haijun
    Luo, Xin
    Zhang, Lan
    Qi, Hongbo
    Zhang, Hua
    Li, Junnan
    BMC PREGNANCY AND CHILDBIRTH, 2024, 24 (01)
  • [32] Prevalence and risk factors of drug induced liver disease: a survey based study in pharmacies
    Juengst, C.
    Graeber, S.
    Klahn, D.
    Wedemeyer, H.
    Lammert, F.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2016, 54 (02): : 131 - 138
  • [33] Utility of Liver Biopsy in the Diagnosis and Management of Possible Drug-Induced Liver Injury in Patients Receiving Antituberculosis Therapy: A Retrospective Study
    Gualano, Gina
    Zace, Drieda
    Mosti, Silvia
    Mencarini, Paola
    Musso, Maria
    Libertone, Raffaella
    Cerva, Carlotta
    Goletti, Delia
    Rianda, Alessia
    Del Nonno, Franca
    Falasca, Laura
    Palmieri, Fabrizio
    INFECTIOUS DISEASE REPORTS, 2023, 15 (06) : 735 - 746
  • [34] Risk factors for irinotecan-induced liver injury: a retrospective multicentre cross-sectional study in China
    Han, Jun
    Liu, Jianhua
    Yu, Zaoqin
    Huang, Rui
    Zhao, Li
    Xu, Yi
    Chen, Min
    He, Guangzhao
    Song, Qiuyan
    Li, Wei
    Zhang, Chengliang
    BMJ OPEN, 2023, 13 (06):
  • [35] Blastocystis incidence, spontaneous clearance, persistence and risk factors in a rural community in Thailand: A prospective cohort study
    Wongthamarin, Kawin
    Trairattanapa, Thanaporn
    Kijanukul, Sirakit
    Kritsilpe, Thanakrit
    Poobunjirdkul, Sarun
    Chuengdee, Warit
    Mungthi, Mathirut
    Leelayoova, Saovanee
    Naaglor, Tawee
    Taamasri, Paanjit
    Suwannahitatorn, Picha
    Ruang-Areerate, Toon
    Piyaraj, Phunlerd
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2020, 13 (03) : 123 - 130
  • [36] Retrospective analysis of risk factors for levofloxacin-induced liver injury
    Amemiya, Takahiro
    Suzuki, Hiroshi
    JOURNAL OF CHEMOTHERAPY, 2023, 35 (08) : 707 - 711
  • [37] Epidemiology, Predisposing Factors, and Outcomes of Drug-Induced Liver Injury
    Bjornsson, Einar S.
    CLINICS IN LIVER DISEASE, 2020, 24 (01) : 1 - +
  • [38] The Risk Factors and Mechanisms of Azole Resistance of Candida tropicalis Blood Isolates in Thailand: A Retrospective Cohort Study
    Leepattarakit, Teera
    Tulyaprawat, Orawan
    Ngamskulrungroj, Popchai
    JOURNAL OF FUNGI, 2022, 8 (10)
  • [39] Sex Differences in the Incidence and Risk Factors of Myocardial Injury in COVID-19 Patients: A Retrospective Cohort Study
    Cheng, Ran
    Liu, Chuan
    Yang, Jie
    Yang, Yuanqi
    Chen, Renzheng
    Ding, Xiaohan
    Gao, Xubin
    Ke, Jingbin
    Yuan, Fangzhengyuan
    He, Chunyan
    Shen, Yang
    Zhang, Limin
    Li, Ping
    Tan, Hu
    Huang, Lan
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [40] Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study
    Lv, Binbin
    Liu, Longshan
    Liu, Xiaoman
    Huang, Min
    Chen, Xiao
    Tang, Kejing
    Wang, Changxi
    Chen, Pan
    FRONTIERS IN PHARMACOLOGY, 2023, 14